TITLE

THREE YEARS OF PATIENT-LED THERAPY IN ULCERATIVE COLITIS WITH A SINGLE AMINOSALICYLATE, BALSALAZIDE: A LONG TERM OBSERVATIONAL STUDY

AUTHOR(S)
Green, J.R.B.; Swan, C.H.J.; Gibson, J.A.; Kerr, G.D.; Swarbrick, E.T.; Thornton, P.C.
PUB. DATE
April 2003
SOURCE
Gut;Apr2003 Supplement 1, Vol. 52, pA69
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Patient-led therapy in ulcerative colitis (UC) may have significant advantages for patients but this has never been formally observed in long term practice. Use of a single therapy effective in acute relapse and maintenance of remission (in different doses) could simplify long term management by enabling patients to choose an appropriate dose. Balsalazide, an aminosalicylate prodrug, is effective and well tolerated at all doses for both these indications in UC. To assess the practicability, safety and efficacy of patient-led dosing, two groups of patients in remission from UC (52 in long-term stable remission (SR) and 76 in recent remission RR were prospectively followed in a 3 year open non-comparative study receiving balsalazide in a variable dose determined by the patient. Symptoms, mucosa infammation, general well-being and adverse events were assessed every 12-14 weeks and laboratory assessments made every 6 months. The average daily dose in both groups was 3g (range 1.5-6g). A total of 23 SR patients (45%) had relapsed by 3 years (median time to relapse 36 months) compared with 45 RR patients (59%) (median time to relapse 22 months) with fewer patients relapsing each successive year in both groups. Clinical scores for SR patients were consistent over the study, while RR patients showed a slight improvement. Both groups needed fewer dose increases over time. Time since last relapse was significantly associated with relapse during the first year of treatment (p<0.033) for SR patients. No adverse medication-related haematological or biochemical changes were recorded. We conclude that long term patient-led maintenance therapy with balsalazide appears to be well tolerated, safe and effective for patients with UC.
ACCESSION #
9747750

 

Related Articles

  • Ellen Beck, Daughter of Dr. Gerson's Patient. Beck, Ellen // Gerson Healing Newsletter;Nov/Dec2003, Vol. 18 Issue 6, p6 

    Presents a letter concerning the benefits of Gerson therapy. Uncertainty on the efficacy of pain killers for ulcerative colitis; Diagnosis of ulcerated colitis.

  • New steroids for IBD: progress report. Hanauer, S.B. // Gut;Aug2002, Vol. 51 Issue 2, p182 

    Discusses the improvement of therapies for ulcerative colitis and Crohn's disease. Absorption efficiency of budenoside; Potency of non-systemic steroids; Efficacy of controlled release formulations.

  • Interferon-β-1a.  // Reactions Weekly;3/12/2011, Issue 1342, p20 

    The article describes the case of a 44-year-old woman who acquired ulcerative colitis while undergoing treatment with interferon-β-1a.

  • Balsalazide.  // Reactions Weekly;1/10/2009, Issue 1234, p10 

    The article describes the case of a 38-year-old man who developed myocarditis while being treated with balsalazide for ulcerative colitis. Following his diagnosis of ulcerative colitis, he was given mesalazine. His medication was replaced to balsalazide and prednisolone. He developed...

  • Sulfasalazine.  // Reactions Weekly;1/14/2012, Issue 1384, p53 

    The article describes the case of a 17-year-old boy who developed drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome after receiving sulfasalazine for ulcerative colitis.

  • Four-Year Maintenance Treatment With Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Data from ULTRA 1, 2, and 3. Colombel, Jean-Frederic; Sandborn, William J; Ghosh, Subrata; Panaccione, Remo; Wolf, Douglas C; Feagan, Brian; Reinisch, Walter; Robinson, Anne M; Huang, Bidan; Skup, Martha; Thakkar, Roopal B; Lazar, Andreas; Kron, Martina // American Journal of Gastroenterology;Nov2014, Vol. 109 Issue 11, p1771 

    OBJECTIVES:The safety and efficacy of adalimumab for patients with moderately to severely active ulcerative colitis (UC) has been reported up to week 52 from the placebo-controlled trials ULTRA (Ulcerative Colitis Long-Term Remission and Maintenance with Adalimumab) 1 and 2. Up to 4 years of...

  • A new use for nicotine patches. Brown, Edwin W. // Medical Update;Nov97, Vol. 21 Issue 5, p4 

    Reports that the nicotine patches can be used in relieving the symptoms of ulcerative colitis. Symptoms of the disease; Study conducted by the researchers from Mayo Clinic on the nicotine patches; Finding of the study on the stool frequency and rectal bleeding of patients who wore nicotine patches.

  • Nicotine may help ulcerative colitis.  // BMJ: British Medical Journal (International Edition);03/22/97, Vol. 314 Issue 7084, p846 

    Reports on the possible benefits of transdermal nicotine in the treatment of ulcerative colitis.

  • ULCERATIVE COLITIS.  // Current Medical Literature: Gastroenterology;2005, Vol. 24 Issue 4, p87 

    The section presents the results of several studies on ulcerative colitis. The topics of the studies were the use of infliximab as rescue therapy for severe to moderately severe ulcerative colitis, the link between ischemic colitis and rofecoxib use and the application of leukocytapheresis in...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics